XtalPi Inc. is a pharmaceutical technology company that focuses on digital drug development solutions, leveraging quantum mechanics and artificial intelligence to enhance the efficiency of drug research and development. Founded in 2014 by a group of quantum physicists at MIT, the company has developed its Intelligent Digital Drug Discovery and Development (ID4) platform, which integrates advanced cloud computing algorithms to aid pharmaceutical firms in critical stages of drug R&D. XtalPi offers various tools, including XtalForc for visual force field calculations, XtalVision for crystal structure predictions, and Renova for platform support of its AI research initiatives. Its comprehensive services encompass crystal structure determination, solid-state testing, small molecule drug design, and collaborations in antibody and peptide research. Based in Cambridge, Massachusetts, with additional offices in China, XtalPi has established strategic partnerships with leading international pharmaceutical companies, demonstrating the broad applicability and recognition of its innovative technologies across the pharmaceutical value chain.
Xellar Biosystems is a biotechnology company that focuses on enhancing drug discovery and development through the integration of artificial intelligence and machine learning. The company offers a research platform that combines advanced computational methods with large-scale wet-lab experiments. This approach allows researchers to utilize simplified models and reductionistic tools, streamlining the processes of drug testing and treatment analysis. By leveraging these technologies, Xellar Biosystems aims to accelerate the development of new pharmaceuticals, ultimately contributing to more efficient and effective healthcare solutions.
NewDEL Biotech
Series A in 2025
Newdel Biotech specializes in drug screening services and the development of innovative biomedical technologies. The company focuses on creating advanced drugs specifically aimed at treating tumors, utilizing DNA Encoded Library technology to enhance the success rates of these treatments. This innovative approach aims to provide tumor patients with next-generation alternative medicines, improving their therapeutic options and outcomes. In addition to drug development, Newdel Biotech also offers consulting services in the biomedical technology sector, contributing to advancements in healthcare solutions.
FuChe Biotech
Seed Round in 2025
FuChe Biotech is a biotechnology startup which Empower a clear future and innovative technology.
Meta Pharmaceuticals
Venture Round in 2025
META Pharmaceuticals is a drug development company focused on creating innovative treatments for autoimmune diseases. The company specializes in the emerging field of immunometabolism, aiming to develop first-in-class drugs that address these conditions. By integrating artificial intelligence with biomedical research, META Pharmaceuticals enhances its ability to analyze and validate new therapeutic targets and their mechanisms of action. This approach accelerates the discovery of targets and facilitates their translation into effective new therapies.
Merda Biopharma
Series A in 2025
Merda Biopharma is a AI-enabled drug discovery technology platform that produces small molecule drugs that helps immune metabolism.
Alternative Bio
Corporate Round in 2025
Alternative Bio is a biotechnology company focused on developing novel therapeutics targeting a previously untapped class of post-translational modifying enzymes.
Orient Biotech
Venture Round in 2025
Orient Biotech is a private biotechnology company developing innovative drugs for underappreciated modified processing enzymes.
Leman Biotech
Series A in 2024
Developer and researcher of novel tumor immunotherapy drugs intended to serve the biotechnology. The company focuses on new tumor immunotherapy drugs based on immunometabolic reprogramming & artificial intelligence (AI), its team has developed the world's first Meta 10 immune metabolism reprogramming technology and established a technology platform for the discovery, development, and production of biological macromolecular drugs and new immune cell drugs.
ReviR Therapeutics
Series A in 2024
ReviR Therapeutics is a genomics-focused company that develops innovative RNA-based medicines aimed at treating cancer, rare genetic disorders, and infectious diseases. The company leverages an artificial intelligence-driven platform to enhance the discovery of therapeutics that target human RNAs. By combining advanced computational techniques with genomic insights, ReviR Therapeutics strives to create transformative therapies that can significantly impact patient care and improve health outcomes for millions.
Leman Biotech
Seed Round in 2024
Developer and researcher of novel tumor immunotherapy drugs intended to serve the biotechnology. The company focuses on new tumor immunotherapy drugs based on immunometabolic reprogramming & artificial intelligence (AI), its team has developed the world's first Meta 10 immune metabolism reprogramming technology and established a technology platform for the discovery, development, and production of biological macromolecular drugs and new immune cell drugs.
Aoshixin
Seed Round in 2024
Aoshixin is a clock chip developer that specializes in the research and development of high-precision, high-reliability clock chips and other related products. Its goods find application in industries such as high-reliability and scientific research devices.
CytoCan
Seed Round in 2023
CytoCan Corp. is a biotechnology company dedicated to the research and development of innovative cancer therapies. The company specializes in creating multi-specific fusion protein drugs through its modular platform technology, which enables the production of proteins that target cancer cells with multiple functions. By identifying unmet medical needs and focusing on difficult-to-treat cancers, CytoCan designs targeted immune therapies aimed at enhancing patients' ability to combat cancer. Through its advanced approach, the company seeks to make significant contributions to the field of oncology and improve treatment outcomes for patients facing challenging cancer diagnoses.
Meta Pharmaceuticals
Seed Round in 2022
META Pharmaceuticals is a drug development company focused on creating innovative treatments for autoimmune diseases. The company specializes in the emerging field of immunometabolism, aiming to develop first-in-class drugs that address these conditions. By integrating artificial intelligence with biomedical research, META Pharmaceuticals enhances its ability to analyze and validate new therapeutic targets and their mechanisms of action. This approach accelerates the discovery of targets and facilitates their translation into effective new therapies.
PhoreMost
Series B in 2021
PhoreMost Limited is a drug discovery company based in Cambridge, United Kingdom, focused on identifying new druggable targets for cancer and other unmet diseases. Since its incorporation in 2014, the company has developed Site-Seeker, a platform that uncovers cryptic druggable sites within the human genome and connects them to therapeutic functions in live-cell contexts. This innovative approach allows PhoreMost to design small molecule drugs based on functionally validated protein fragments. By collaborating with a global network of academic and industrial partners, the company aims to bring novel targeted therapies to market more efficiently, ultimately benefiting patients through cost savings and the development of first-in-class drug discovery programs for potential licensing to pharmaceutical companies.
METiS Pharmaceuticals
Angel Round in 2020
Jitai Medicine (METiS) is a biotechnology company that uses artificial intelligence to drive drug delivery and drug discovery. It combines advanced technologies like artificial intelligence, machine learning, and quantum simulation to achieve more effective design of innovative delivery materials, drug candidate selection and formulation design, "programmable nucleic acid drug" development, and nucleic acid delivery design.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.